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Background: Thalassemias (Thal) are forms of inherited autosomal recessive blood disorders arising out of
mutations in the chromosomes 11 or 16. These disorders lead to poor oxygen delivery to blood vessels and
consequent splenomegaly, bone deformities, and shorter life spans. The most common detection methods for Thal
are complete blood count (CBC) followed by electrophoresis and molecular diagnosis methods, such as
high-performance liquid chromatography (HPLC) and polymerase chain reaction (PCR) genotyping. These methods
involve sophisticated instrumentations and are cumbersome and expensive.
Results: In this study an innovative spectral detection method, based on the fluorescence spectra of a set of
biomolecules (tyrosine, tryptophan, nicotinamide adenine dinucleotide, and flavin adenine dinucleotide and
porphyrins) found in blood components is presented. An algorithm based on the spectral features of such
biomolecules of blood components of 20 Thal patients (10 female and 10 male) and 18 age adjusted normal
controls (4 female and 14 male) demonstrate reasonable level of classification with sensitivity and specificity values
exceeding 90%.
Conclusion: This new technique could be of significant value for Thal detection, diagnosis, and subsequent genetic
counselling and could be adapted for use in small primary health centres.
Keywords: Blood plasma, Synchronous fluorescence excitation spectra, red blood cells (RBC), receiver operator
curve (ROC), ThalassemiaBackground
Thalassemias (Thal) are inherited autosomal recessive
blood disorders caused by α or β globin chain imbal-
ances. Both imbalances lead to abnormal haemoglobin
molecules that cause anaemia, which is a characteristic
symptom of Thal. Most cases of α Thal are detected
during new-borns screenings, but β Thal is not apparent
until the patients are 4–6 months old.
The α globin chain is encoded by four genes, one or
more of which can be mutated or missing. The affected
genes cause different levels of symptoms. For example,
when only one gene is abnormal, the child is a silent α
Thal carrier. A patient with two missing or mutated
genes is described as α Thal minor or as having the Thal
α trait. Patients with three mutated Thal genes have* Correspondence: masila123@gmail.com
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unless otherwise stated.haemoglobin H disease, and those with four missing or
mutated genes have a condition known as α Thal major
or hydrops fetalis [1].
The β Thal is caused by mutations in the genes that
code for the β globin chain. Three forms are well known:
Thal minor, Thal intermedia, and Thal major. Individ-
uals with β Thal major usually present with severe an-
aemia within the first 2 years of life, poor growth, and
skeletal abnormalities during infancy. Affected children
require regular blood transfusions throughout their lives.
The β Thal intermedia are less severe than β Thal major
and therefore might require less frequent blood transfu-
sions. Transfusion-dependent patients develop iron over-
loads and require chelation therapy to remove the excess
iron. Bone marrow transplants can be curative for some
children with β Thal major.
Thal is carried by 150 million people, representing 3%
of the world’s population, and is clinically apparent in 15
million people. It is particularly associated with peopleLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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of Thal are more common in specific parts of the world.
α Thal is common in parts of the world where malaria is
or had previously been endemic. β Thal is much more
common in Mediterranean countries, such as Greece,
Italy, and Spain. Many Mediterranean islands, including
Cyprus, Sardinia, and Malta, have significantly high inci-
dence rates of severe β Thal, constituting a major public
health problem. For example, in Cyprus, 1 in 7 individuals
carry the gene, which translates to 1 in 49 marriages
between carriers and 1 in 158 new born who are expected
to have β Thal major [2].
On the other hand, α Thal is more common in Southeast
Asia, India, the Middle East, and Africa. The carrier rates
for α Thal are 1 in 7 for Cypriots, 1 in 12 for Greeks, 1
in 12 for Indians and 1 in 25 for Pakistanis. Thal is also
common in the Kingdom of Saudi Arabia, particularly in
the eastern and southern provinces. Premarital screening
and genetic counselling centres associated with the Saudi
Arabian Ministry of Health have reported a Thal prevalence
rate of 18.5 cases per 1000 citizens (18 carriers and 0.5 with
serious level of disease) [3].
Currently, many methods are being used to screen and
diagnose Thal. The osmotic fragility test is commonly
used for Thal screening, despite its low specificity. The
most specific Thal diagnosis methods are haemoglobin
(Hb) electrophoresis phenotyping [4] or high-performance
liquid chromatography (HPLC) [5]. Other commonly used
methods include polymerase chain reaction (PCR) and
enzyme- linked immuno sorbent assay (ELISA) [6].
However, these techniques are expensive and cannot be
used as routine laboratory tests in small hospitals or clinics.
In this context, the present study describes the potential ap-
plication of a spectral technique as a simple, inexpensive,
and fast diagnostic protocol that could be employed in
primary health centres in the Asian, Arabian, and African
countries (which have highest prevalence of Thal).
The objective of the present study is to demonstrate
the potential of spectral haemoglobinopathic diagnosis
using well-defined Thal cases as examples. The spectra of
blood cellular components and extracellular plasma could
provide substantial insight into the subjects’ pathologies.
Methods
Experiments were performed on blood plasma and red
blood cell (RBC) samples from Thal patients and age-
adjusted healthy controls.
Exactly 5 ml of venous blood from 18 healthy volunteers
(age range: 17 to 32 years) were collected in violet sterile
vials that contained the anticoagulant EDTA. The vials
were gently rocked five times to adequately mix the EDTA
with the whole blood, and the samples were centrifuged at
3000 rotational speed (rpm) for 15 minutes. Clear, pale,
greenish-yellow plasma supernatants were obtained bysuch centrifugation. A total of 1.5 ml of supernatant
was removed from the top layer for spectrofluorimetric
analysis, leaving the buffy coat, the formed elements,
and the undisturbed sediment. The blood plasma samples
were subjected to synchronous fluorescence excitation
spectral analyses without any other treatment.
Next, the buffy coats, which contained mostly white
blood cells (WBCs) (e.g., lymphocytes), were removed
and discarded, and exactly 1 ml of the thick formed ele-
ments from the bottom layer, which contained mostly
RBCs, was removed to a sterile vial and mixed with 2 ml
of analytical grade acetone. Proper care was taken to en-
sure that the formed elements did not develop lumps.
After thorough mixing to enable the acetone to extract
fluorophores within and around the cells, the samples were
centrifuged again (3000 rpm for 15 minutes). The resulting
supernatant was subjected to fluorescence emission spectra
analysis at an excitation wavelength of 400 nm.
The same protocol was used to process blood samples
from confirmed Thal patients (α and β major) obtained
from King Khalid University Hospital, Riyadh, Saudi Arabia
from where the Institutional Review Board (IRB) approval
had been obtained (approval number 12/3594/IRB). The
patients were informed about the investigation, and proper
consent was obtained. The Thal subjects consisted of 20
Thal patients (10 female and 10 male) with a median age
of 25 years (range: 17–32 years). The age and sex adjusted
normal controls (N = 18) were students, researchers, and
staff nurses from whom informed consents obtained.
The following side line observations were noteworthy:
The ratio between the plasma and cellular component
volumes in normal patient samples was approximately
1.2:1, while the same ratio in Thal patient samples was
nearly 1.8:1. Control plasma was greenish- yellow in colour,
while patient plasma was yellowish in colour.
Instrumentation
The instrument used was a spectrofluorometer (PerkinElmer
Luminescence LS 55) capable of collecting excitation,
emission, and synchronous spectra in the 200–800 nm
range. An excitation and emission slit width of 10 nm
and scan speeds of 1000 nm/min were used. The sam-
ples were placed in quartz cuvettes and illuminated by
a specified wavelength of light with a 10-nm spectral
width and a spot size of 3 × 2 mm. The power at the
point of illumination was approximately 20 μW, which
was too low to induce photo bleaching. This finding
was confirmed by repeating the experiment three times
for each sample and observing no inter-replicate spec-
tral differences.
Three types of spectra are measured in the field of
fluorescence spectroscopy. In fluorescence emission spectra
(FES), one particular wavelength is selected for the excita-
tion of a molecule, and the fluorescence emission spectrum
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mined range. The reverse is true of fluorescence excitation
spectra (FXS), in which the peak emission band of a mol-
ecule is selected, and the excitation grating is rotated to
scan the excitation spectra. In synchronous excitation spec-
tra (SXS), both gratings are synchronously rotated at offsets
of 40 nm or 70 nm to obtain the fluorescence excitation
bands for every molecule in the predetermined range.
The wavelength offset and scan range are not unique;
they are determined empirically by trial and error, for a
given set of experimental protocol. After analysing other
offsets, including 10 nm and 30 nm, it was determined
that the 70 nm offset provided excellent resolution and
good contrast between the normal and Thal samples be-
cause 70 nm is the Stokes shift [7,8] of the most import-
ant biofluorophores (e.g., tryptophan) in blood plasma.
Hence, all the results presented for plasma were based
on the synchronous excitation spectra (SXS).
Results
Figure 1 shows the FES of the acetone extracts of blood
cellular components from normal (a) and Thal samples
(b), both of which were excited at 400 nm. Both had
peaks at 470 nm, mostly due to the Raman acetone band
in which the fluorescent bio molecules were suspended;
the two additional bands at 580 nm and 630 nm repre-
sented the basic and neutral forms of porphyrin, respect-
ively. By calculating the ratio R1 = I630/I580, which was the
intensity ratio between the bands at 630 and at 580 nm,
we obtained a value of approximately 1.2 for the normal
samples and 0.5 for the Thal samples. The ratio values for
these two sets are shown in Figure 2 and indicate a clear






















Figure 1 Fluorescence emission spectra (FES) of RBC acetone extractFigure 3(a) shows a typical synchronous excitation
spectrum (SXS) of plasma of an age-adjusted normal
control, a 25 year old female. The spectrum has three
main peaks at 290 nm, 370 nm, and 450 nm. Of these,
the 290 nm peak corresponded to the excitation peak
of the amino acid tryptophan, the 370 nm peak corre-
sponded to that of the coenzyme nicotinamide adenine
dinucleotide (NADH), and the 450 nm peak corresponded
to that of the metabolite flavin adenine dinucleotide
(FAD). A shoulder was apparent at 275 nm on the shorter
wavelength side of the 290 nm peak due to the amino acid
tyrosine. The intensities of these peaks (in arbitrary units)
were 225 for the 290 nm band, 70 for the 370 nm band,
40 for the 450 nm band, and approximately 160 for the
275 nm shoulder.
In contrast, a typical synchronous excitation spectrum
(SXS) of plasma of a Thal patient (female, age 25) is
shown in Figure 3(b). There were two major differences
between the normal and Thal patient samples. The first
difference was that the peaks were conspicuously out of
proportion. The second was that the overall intensities
were significantly lower in the Thal patients than in the
normal controls. For example, the relative intensity ratio
R2 = I290/I370 (which was the ratio of the peak intensities
due to tryptophan and NADH) for the normal control
was 2.4, while for the Thal patient value was 8.7. The
two fluorescent biomarkers, tryptophan and NADH,
were out of proportion in Thal patients, as indicated by
the approximately 3.6 fold higher R2 value for Thal patients.
The scatter plot for R2, shown in Figure 4, classifies the two
sets quite well.
Similarly, R3, which was defined as I450/I370, or the ra-





























a- Normal cotrols = 1.19
b- Thalassemia patients = 0.51
a b
Figure 2 Distribution of R = I630/I580 ratios, as obtained from Figure 1. a- Normal controls b- Thalassemia patients.
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the Thal patients (Figure 3). We found that the mean of
R3 is 0.86 for the controls and 19.7 for the Thal patients.
Using this classification method, it was possible to
achieve specificity and sensitivity rates exceeding 96%
because the FAD levels were abnormally high in Thal
patients. See Figure 5.
Another unique feature was the relative peak elevation at
275 nm compared with that at 290 nm in the Thal patients,
























Figure 3 Synchronous excitation spectra (SXS) of plasma. a- Normal coclear distinct band in the UV region at 290 nm with a weak
shoulder at 275 nm, but the reverse was true for the Thal
patient samples. The R4 ratio of I275/I290 was approximately
0.8 for the normal samples but was increased to 0.9-2.1
(average: 1.39) for the Thal samples, as shown in Figure 6.
Thus, the peak at 275 nm (due to tyrosine) was elevated 1.5
times in Thal patients.
Because the present study was limited to 38 samples
(20 Thal and 18 control) only a simple, basic statistical ana-


































Figure 4 Distribution of R2 = I290/I370 ratios, as obtained from Figure 3. a- Normal controls b- Thalassemia patients.
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is the ratio of the intensities at 630 and 580 nm). For each
ratio, ID 1 indicates a normal sample, and 2 indicate a Thal
patient sample; only one parameter, I290, was based on the
absolute rather than the relative sample intensity. The
p-value for the two-tailed test was (less than 0.05) indicat-
ing good data separation. From these data, an ROC curve
was drawn for the five ratio parameters. Figure 7 shows the
ROC for R1, which was obtained from the FES of acetone
extract of RBC, and the absolute intensity parameter at
290 nm for the plasma. Figure 8 shows the ROC for





















Figure 5 Distribution of R3 = I450/I370 ratios, as obtained from Figure 3It is to be noted that, the ROC for the R1, the runs
along the two axes, indicating that this parameter is
capable of classifying the samples with sensitivity and
specificity levels of 100% each. The next best parameter is
the R3 (ratio of the 450 nm and 370 nm intensities), which
has sensitivity and specificity levels of 94% each (Table 2).
Discussion
Thalassemias are blood disorders that lead to many com-
plications, including fatigue, bone deformities, shortness of
breath, growth failure, splenomegaly, and decreased life
span. In developing countries, such as India and Pakistan,21 24 27 30 33 36 39
nt Number
a-Normal  controls = 0.86
b-Thalassemia  patients = 19.77

























a- Normal controls= 0.89
b- Thalassemia patients= 1.39
Figure 6 Distribution of R4 = I275/I290 ratios, as obtained from Figure 3. a- Normal controls b- Thalassemia patients.
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or scientific counselling. In this context, the results of
this study indicate that a simple spectrofluorimetric
detection method could offer new prospects for inexpen-
sive Thal detection.
A set of fluorescent blood biomarkers has been identified
and quantified in Thal patients by employing synchronous
excitation and fluorescence emission spectra. These spectra
were compared to those of age -adjusted normal controls.
The two sets showed distinctly different spectral features.
A spectral feature of cellular components is consid-
ered first.
We always measured the relative peak intensity at
630 nm (neutral porphyrin) with respect to the peak at
580 nm (basic porphyrin) as an internal reference. This
ratio is dependent only on the molecules present in the
sample and not on instrument factors, and it has been
used extensively to detect cancer. In cancer patients,
this ratio is approximately 3 or higher, while in normal
controls, it is approximately 1. Thus, malignancy generally
increases this ratio 3 fold [9,10]. In contrast, this ratio inTable 1 Group statistics and independent 2-tailed t-test
Parameter ID N Mean Std. devia
PK_290 1.00 18 144.4833 88.1618
2.00 20 24.0410 29.9152
R1_630_580 1.00 16 1.1913 0.2976
2.00 18 0.5117 0.1164
R2_290_370 1.00 18 2.4106 1.1564
2.00 20 8.7770 6.2639
R3_450_370 1.00 18 0.8678 0.9977
2.00 20 19.7755 19.1632
R4_275_290 1.00 18 0.8994 0.1070
2.00 20 1.3465 0.3916Thal patients is approximately 50% of the control ratio. It
is well known that the RBC content is significantly lower
in Thal patients than in normal controls. In fact, the RBC
content is the first test and classification factor for Thal.
For all Thal cases in the present study, the RBC contents
varied from 2 to 3.5 million/μL, with a mean value of 3
million/μL. In contrast, the RBC values for the normal
controls, varied from 4.5 to 5.75 million/μL, with a mean
value of 5 million/μL. This difference was reflected in our
spectral analysis, shown in Figure 1 which is the fluores-
cence spectra of the cellular component acetone extracts.
These findings provide direct spectroscopic evidence of
the reduced RBC counts in Thal patients. As expected, we
obtained a one to one correlation between the microscopic
cell counts and the spectroscopic molecular diagnoses
(Figures 1 and 2).
However, it was surprising to observe the effects of
defective haemoglobin on the fluorescent plasma bio-
markers (tyrosine, tryptophan NADH, and FAD), as
shown in Figure 2 to Figure 6. Of these biomarkers, the











Figure 7 Receiver operator curve (ROC) obtained from the statistical evaluation of the data for R1 and the absolute intensity at
290 nm. Note that, for R1, the curves run parallel to the X and Y axes.
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in many cellular redox activities. All these molecules
are misregulated in Thal and cancer patients [8].
The most striking observation was the abnormal ele-
vation in FAD levels (SXS at 450 nm) and the equally
abnormal decrease in NADH levels (SXS at 370 nm); the
ratio between these two biomarkers provided a diagnostic
accuracy of 94%. There could be many reasons for these
aberrations. For example, RBCs decays at a much fasterFigure 8 Receiver operator curve (ROC) for the other ratio parameterrate in Thal patients than in normal controls due to the
faulty globins, and FAD is a well-known metabolite that is
involved in all cellular redox activities. In the decay of one
RBC, two NADH molecules are involved, which could be
the main reason for the abnormal decrease in NADH
levels. Another possible reason is that NADH might trans-
fer a significant amount of excitation energy to FAD due
to the strong overlap of the NADH emission band and the
FAD absorption band. Similar reductions in NADH levelss, obtained from the plasma SXS.
Table 2 Sensitivity, specificity, and area under the curve








R1_630_580 1.000 0.83 100 100
R2_290_370 0.922 3.5 81.3 88.9
R3_450_370 0.983 1.9 93.8 94.6
R4_275_290 0.825 1.0 87.5 77.5
PK@290 0.958 51 100 90
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and urine samples from patients with advanced and ag-
gressive cancers, such as Hepatocellular carcinoma [8].
As shown in Figure 3, the first peak in normal plasma
samples occurred at 290 nm with a shoulder at 275 nm.
These peaks were reversed in Thal patient plasma sam-
ples. The ratio R3 = I275/I290 was approximately 0.8 for
control samples and 1.4 for patient samples. Tyrosine
and tryptophan are closely related essential amino acids.
In Thal patients, the low oxygen levels that are caused
by abnormal haemoglobin might upset the equilibrium
of these amino acids.
Some essential statistics were calculated for the classi-
fications of the normal (set 1) and Thal diseased patients
(set 2), employing independent ratio parameter. R1 is the
ratio of two types porphyrin concentrations found in
cellular components; R2 is the ratio for FAD/NADH
concentration found in plasma; R3 is the ratio for tyrosine/
tryptophan concentration found in plasma. For each one of
them, specificity and sensitivity exceeded 90%.
Conclusion
In this preliminary spectral investigation on fluorescent
biomarkers in Thal blood samples involving a limited
number (N = 20) of known Thalassemia cases and age-
adjusted normal controls (N = 18), distinction between
the two sample sets could be achieved with an accuracy
that exceeded 90%. This result is only indicative of the
efficacy of spectral diagnosis. In the near future, we plan to
conduct a large-scale field trial to distinguish between
Thal major, minor, and intermedia, which will confer viable
clinical value to this technique.
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